Clopidogrel and proton pump inhibitors boon or bane;Clopidogrel und Protonenpumpeninhibitoren Fluch oder Segen?

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 5, 2010, Pages 203-206

  Labenz, J ^a,b   Meyners, W ^a   Petersen, K U ^c  

^a Ev Jung Stilling Krankenhaus   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Clopidogrel; Cytochrome P450 2C19; Drug interaction; Protone pump inhibitors

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ESOMEPRAZOLE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TICLOPIDINE;

CARDIOVASCULAR DISEASE; GASTROESOPHAGEAL REFLUX; HEART MUSCLE ISCHEMIA; NOTE; STENT;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RISK FACTORS; TICLOPIDINE;

EID: 76249099534     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1244837     Document Type: Note

References (24)

1. Adamopoulos A B., Sakizlis G N., Nasothimiou E G., et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomised crossover study. J Cardiovasc Pharmacol 2009 54 163-168
2. Bonzel T, Erbel R, Hamm C W., et al. Perkutane Koronarinterventionen (PCI). Clin Res Cardiol 2008 97 513-547
3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996 348 1329-1339
4. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009 54 1149-1153
5. Fischbach W, Malfertheiner P, Hoffmann J C., et al. S3-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2009 47 68-102
6. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. Brit Med J 2008 336 2-3
7. Gilard M, Arnaud B, Cornily J C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 51 256-260
8. Grines C L., Bonow R O., Casey D E Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007 115 813-818
9. Heidelbaugh J J., Goldberg K O., Inadomi J M. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol 2009 104 S27-S32
10. Ho P M., Maddox T M., Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 301 937-944
11. Juurlink D N., Gomes T, Ko D T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 180 713-718
12. Lahner E, Annibale B, Delle Fave G. Systemic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009 29 1219-1229
13. Li X Q., Andersson T B., Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabol Dispos 2004 32 821-827
14. Mega J L., Close S AL, Wiviott S D., et al. Cytochrome P-450 polymorphisms and response to Clopidogrel. N Engl J Med 2009 360 354-362
15. Ng F H., Lam K F., Chang C M., et al. Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 2008 77 173-177
16. ODonoghue M L., Braunwald E, Antman E M., et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009 374 989-997
17. Petersen K U. Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel. Arzneimittelforschung 2009 59 213-227
18. Rosemary J, Adithan C. The pharmacogenetics of CYP 2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol 2007 2 93-109
19. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009 101 714-719
20. Silber S, Borggrefe M, Böhm M, et al. Medikamente freisetzende Koronarstents (DES) und Medikamente freisetzende Ballonkatheter (DEB): Aktualisierung des Positionspapiers der DGK. Clin Res Cardiol 2008 97 548-563
21. Siller-Matula J M., Spiel A O., Lang I M., et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009 157,148 e1-5
22. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 360 363-375
23. Taha A S., McCloskey C, Prasad R, Bezylak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009 374 119-125
24. Wallentin N, Becker R C., Budaj A, et al. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 361 1045-1057